Duda Lab

Talele NP, Kumra H, Gomes-Santos IL, Ho WW, Andersson P, Siwicki M, Huang P, Duda DG, Pittet MJ, Fukumura D, Jain RK

IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity.
J Immunother Cancer. 2025;13(5):ePub - PMID: 40413022 - PMCID: PMC12104899 - DOI: 10.1136/jitc-2024-011404

Duda D, Liu X, Liu Z, Kobayashi T, Lei PJ, Shi Y, Yuan D, Wang J, Li M, Matsui A, Mafra K, Huang P, Kuang M, Bod L

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular Carcinoma.
Res Sq. 2025;:ePub - PMID: 40321752 - PMCID: PMC12047993 - DOI: 10.21203/rs.3.rs-6355345/v1

Gkika E, Firat E, Adebahr S, Graf E, Popp I, Eichhorst A, Radicioni G, Lo SS, Spohn SKB, Nestle U, Nicolay NH, Niedermann G, Grosu AL, Duda DG

A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
Radiother Oncol. 2025;207:110889 - PMID: 40209858 - DOI: 10.1016/j.radonc.2025.110889

Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, Chiorean EG, Philip PA

S2303: phase II/III trial of paclitaxel + ramucirumab +/- nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)
Future Oncol. 2025;21(11):1325-1331 - PMID: 40155326 - PMCID: PMC12051544 - DOI: 10.1080/14796694.2025.2485020

Liu X, Liu Z, Kobayashi T, Lei PJ, Shi Y, Yuan D, Wang J, Li M, Matsui A, Mafra K, Huang P, Kuang M, Bod L, Duda DG

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular Carcinoma.
bioRxiv. 2025;:ePub - PMID: 40093175 - PMCID: PMC11908210 - DOI: 10.1101/2025.03.04.641494

Yan J, Jiang Z, Zhang S, Yu Q, Lu Y, Miao R, Tang Z, Fan J, Wu L, Duda DG, Zhou J, Yang X

Spatial-temporal heterogeneities of liver cancer and the discovery of the invasive zone.
Clin Transl Med. 2025;15(2):e70224 - PMID: 39924620 - PMCID: PMC11807767 - DOI: 10.1002/ctm2.70224

Ren J, Amoozgar Z, Uccello TP, Lei PJ, Zhao Y, Ho WW, Huang P, Kardian A, Mack SC, Duda DG, Xu L, Jain RK

Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma.
Proc Natl Acad Sci U S A. 2025;122(4):e2319474122 - PMID: 39841145 - PMCID: PMC11789170 - DOI: 10.1073/pnas.2319474122

Tesfay MZ, Zhang Y, Ferdous KU, Taylor MA, Cios A, Shelton RS, Simoes CC, Watters CR, Barro O, Elliott NM, Mustafa B, Chamcheu JC, Graham AL, Washam CL, Alkam D, Gies A, Byrum SD, Giorgakis E, Post SR, Kelly T, Ying J, Moaven O, Chabu CY, Fernandez-Zapico ME, Duda DG, Roberts LR, Govindarajan R, Borad MJ, Cannon MJ, Basnakian AG, Nagalo BM

Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.
Mol Ther Oncol. 2024;32(4):200913 - PMID: 39758249 - PMCID: PMC11697550 - DOI: 10.1016/j.omton.2024.200913

Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
J Immunother Precis Oncol. 2024;7(4):255-262 - PMID: 39524465 - PMCID: PMC11541930 - DOI: 10.36401/JIPO-24-6

Morita S, Lei PJ, Shigeta K, Ando T, Kobayashi T, Kikuchi H, Matsui A, Huang P, Pittet MJ, Duda DG

Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma.
Cancer Immunol Res. 2024;13(2):162-170 - PMID: 39514263 - PMCID: PMC11788650 - DOI: 10.1158/2326-6066.CIR-24-0324

Pal R, Krishnamoorthy M, Matsui A, Kang H, Morita S, Taniguchi H, Kobayashi T, Morita A, Choi HS, Duda DG, Kumar ATN

Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity.
Cancer Res. 2024;85(3):618-632 - PMID: 39514403 - PMCID: PMC11967911 - DOI: 10.1158/0008-5472.CAN-24-0880

LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO

Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;103(6):490-497 - PMID: 39427654 - PMCID: PMC12006443 - DOI: 10.1159/000541250

Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Johnston A, Olugbami JO, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
ACS Pharmacol Transl Sci. 2024;7(10):3155-3169 - PMID: 39416967 - PMCID: PMC11475281 - DOI: 10.1021/acsptsci.4c00358

Park RJ, Parikh M, Pappas L, Sade-Feldman M, Kulkarni AS, Bi L, LaSalle TJ, Galway A, Kuhlman C, Blaszkowsky LS, Meyerhardt JA, Enzinger PC, Biller L, Allen JN, Kagey MH, Baum J, Sirard C, Duda DG, Zhu AX, Abrams TA, Hacohen N, Ting DT, Mehta A, Goyal L

Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
medRxiv. 2024;:ePub - PMID: 39417106 - PMCID: PMC11483019 - DOI: 10.1101/2024.10.08.24315092

Ho AY, Shiao S, Kobald SA, Chen J, Duda DG, Ly A, Bossuyt V, Cho HL, Arnold B, Knott S, Gupta GP, McAndrew P, Karlan S, Tighiouart M, Muzikansky A, Basho R, McArthur H

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;42(36):4282-4293 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003

Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer Biomark. 2024;41(1):83-91 - PMID: 39269823 - PMCID: PMC11491993 - DOI: 10.3233/CBM-230431

Sivanand S, Gultekin Y, Winter PS, Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT, Crowder K, Kunchok T, Lau AN, Darnell AM, Jefferson A, Morita S, Duda DG, Aguirre AJ, Wolpin BM, Henning N, Spanoudaki V, Maiorino L, Irvine DJ, Yilmaz OH, Lewis CA, Vitkup D, Shalek AK, Vander Heiden MG

Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - PMCID: PMC11450831 - DOI: 10.1038/s42255-024-01105-9

Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Mol Cancer. 2024;23(1):156 - PMID: 39095771 - PMCID: PMC11295620 - DOI: 10.1186/s12943-024-02060-5

Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Olugbami JO, Johnston A, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
bioRxiv. 2024;:ePub - PMID: 38585757 - PMCID: PMC10996603 - DOI: 10.1101/2024.03.27.587062

Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z

Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
medRxiv. 2024;:ePub - PMID: 38559070 - PMCID: PMC10980136 - DOI: 10.1101/2024.03.14.24304306

Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564

Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin SM, Matsui A, Hernandez A, Pu Z, Halvorsen S, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Sassi S, Bardeesy N, Ho WJ, Jain RK, Duda DG

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486

Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Dror Michaelson M, Lee RJ, Duda DG

The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091

Pal R, K M, Matsui A, Kang H, Morita S, Taniguchi H, Kobayashi T, Morita A, Choi HS, Duda DG, Kumar ATN

In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.
Res Sq. 2023;:ePub - PMID: 37961361 - PMCID: PMC10635296 - DOI: 10.21203/rs.3.rs-3222037/v1

Morita S, Kikuchi H, Birch G, Matsui A, Morita A, Kobayashi T, Ruan Z, Huang P, Hernandez A, Coyne EM, Shin SM, Yarchoan M, Mino-Kenudson M, Romee R, Ho WJ, Duda DG

Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models.
bioRxiv. 2023;:ePub - PMID: 37961529 - PMCID: PMC10634718 - DOI: 10.1101/2023.10.20.563378

Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Cancers (Basel). 2023;15(19):ePub - PMID: 37835569 - PMCID: PMC10571776 - DOI: 10.3390/cancers15194875

Franses JW, Duda DG

Scirrhous HCC: Another 'omic thread in the HCC tapestry.
Hepatology. 2023;79(4):747-748 - PMID: 37725712 - DOI: 10.1097/HEP.0000000000000609

Kashiwagi R, Funayama R, Aoki S, Matsui A, Klein S, Sato Y, Suzuki T, Murakami K, Inoue K, Iseki M, Masuda K, Mizuma M, Naito H, Duda DG, Unno M, Nakayama K

Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment.
Cancer Sci. 2023;114(11):4286-4298 - PMID: 37688308 - PMCID: PMC10637054 - DOI: 10.1111/cas.15952

Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A, Kitahara S, Necula L, Matei L, Dragu D, Neagu AI, Bleotu C, Diaconu CC, Popescu I, Duda DG

Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Gastric Cancer. 2023;26(6):934-946 - PMID: 37668884 - PMCID: PMC12316475 - DOI: 10.1007/s10120-023-01429-7

Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO

Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Oncology. 2023;101(11):730-737 - PMID: 37467732 - PMCID: PMC10614568 - DOI: 10.1159/000531870

McCullum L, Shin J, Xing S, Beekman C, Schuemann J, Hong T, Duda D, Mohan R, Lin S, Correa-Alfonso CM, Domal S, Withrow J, Bolch W, Paganetti H, Grassberger C

Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4D Blood Flow Simulations.
Int J Radiat Oncol Biol Phys. 2023;116(5):1226-1233 - PMID: 36739919 - PMCID: PMC10363211 - DOI: 10.1016/j.ijrobp.2023.01.054

Gkika E, Firat E, Adebahr S, Graf E, Popp I, Radicioni G, Lo SS, Nestle U, Nicolay NH, Niedermann G, Duda DG, Grosu AL

Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
NPJ Precis Oncol. 2023;7(1):24 - PMID: 36864234 - PMCID: PMC9981559 - DOI: 10.1038/s41698-023-00358-z

Gupta N, Ochiai H, Hoshino Y, Klein S, Zustin J, Ramjiawan RR, Kitahara S, Maimon N, Bazou D, Chiang S, Li S, Schanne DH, Jain RK, Munn LL, Huang P, Kozin SV, Duda DG

Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.
Cancers (Basel). 2023;15(4):ePub - PMID: 36831366 - PMCID: PMC9954510 - DOI: 10.3390/cancers15041021

Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, Matsui A, Pu Z, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Bardeesy N, Ho WJ, Jain RK, Duda DG

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
bioRxiv. 2023;:ePub - PMID: 36747853 - PMCID: PMC9901023 - DOI: 10.1101/2023.01.26.525680

Boucher Y, Posada JM, Subudhi S, Kumar AS, Rosario SR, Gu L, Kumra H, Mino-Kenudson M, Talele NP, Duda DG, Fukumura D, Wo JY, Clark JW, Ryan DP, Fernandez-Del Castillo C, Hong TS, Pittet MJ, Jain RK

Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.
Clin Cancer Res. 2023;29(8):1605-1619 - PMID: 36749873 - PMCID: PMC10106451 - DOI: 10.1158/1078-0432.CCR-22-1630

Chamseddine I, Kim Y, De B, Naqa IE, Duda DG, Wolfgang JA, Pursley J, Wo JY, Hong TS, Paganetti H, Koay EJ, Grassberger C

Predictive Model of Liver Toxicity to Aid the Personalized Selection of Proton vs Photon Therapy in Hepatocellular Carcinoma.
Int J Radiat Oncol Biol Phys. 2023;116(5):1234-1243 - PMID: 36739920 - PMCID: PMC12273456 - DOI: 10.1016/j.ijrobp.2023.01.055

Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M

Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
Gut. 2023;72(6):1196-1210 - PMID: 36596711 - DOI: 10.1136/gutjnl-2022-328428

Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget. 2022;13:1314-1321 - PMID: 36473155 - PMCID: PMC9726202 - DOI: 10.18632/oncotarget.28322

Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y

Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Anticancer Res. 2022;42(11):5205-5215 - PMID: 36288859 - DOI: 10.21873/anticanres.16027

Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson Junior PLS, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers.
Hepatology. 2022;77(6):1943-1957 - PMID: 36052732 - DOI: 10.1002/hep.32769

Dima SO, Dumitraşcu T, Popescu I, Duda DG

Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
Chirurgia (Bucur). 2022;117(4):407-414 - PMID: 36049097 - DOI: 10.21614/chirurgia.2772

Munoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA

Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis.
Sci Rep. 2022;12(1):14449 - PMID: 36002545 - PMCID: PMC9402568 - DOI: 10.1038/s41598-022-15948-3

How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
EJHaem. 2022;3(2):434-442 - PMID: 35846042 - PMCID: PMC9175677 - DOI: 10.1002/jha2.408

Saulnier Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Clin Cancer Res. 2022;28(18):3950-3957 - PMID: 35833850 - PMCID: PMC9481695 - DOI: 10.1158/1078-0432.CCR-22-1169

Morita S, Duda DG

Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
Gut. 2022;72(4):608-610 - PMID: 35772925 - PMCID: PMC10435277 - DOI: 10.1136/gutjnl-2022-327782

Martin JD, Lanning RM, Chauhan VP, Martin MR, Mousa AS, Kamoun WS, Han HS, Lee H, Stylianopoulos T, Bawendi MG, Duda DG, Brown EB, Padera TP, Fukumura D, Jain RK

Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition.
Clin Cancer Res. 2022;28(14):3076-3090 - PMID: 35584239 - PMCID: PMC9355624 - DOI: 10.1158/1078-0432.CCR-22-0486

Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X, Fan X

VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
J Transl Med. 2022;20(1):212 - PMID: 35562734 - PMCID: PMC9102726 - DOI: 10.1186/s12967-022-03416-5

Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG

Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051

Hauth F, Roberts HJ, Hong TS, Duda DG

Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.
Int J Mol Sci. 2022;23(4):ePub - PMID: 35216045 - PMCID: PMC8879105 - DOI: 10.3390/ijms23041926

Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Nat Commun. 2022;13(1):758 - PMID: 35140208 - PMCID: PMC8828745 - DOI: 10.1038/s41467-022-28279-8

Hauth F, Ho AY, Ferrone S, Duda DG

Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
JAMA Oncol. 2021;7(7):1051-1059 - PMID: 33885725 - PMCID: PMC8668197 - DOI: 10.1001/jamaoncol.2021.0168

Gkika E, Adebahr S, Brenner A, Schimek-Jasch T, Radicioni G, Exner JP, Rühle A, Spohn SKB, Popp I, Zamboglou C, Sprave T, Firat E, Niedermann G, Nicolay NH, Nestle U, Grosu AL, Duda DG

Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies.
Cancers (Basel). 2021;13(22):ePub - PMID: 34830880 - PMCID: PMC8616228 - DOI: 10.3390/cancers13225725

Klein S, Duda DG

Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas.
Cancers (Basel). 2021;13(19):ePub - PMID: 34638408 - PMCID: PMC8507866 - DOI: 10.3390/cancers13194919

Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
NPJ Precis Oncol. 2021;5(1):62 - PMID: 34188163 - PMCID: PMC8242049 - DOI: 10.1038/s41698-021-00197-w

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Possada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain, RK, Vander Heiden MG

Fatty acid synthesis is required for breast cancer brain metastasis
Nature Cancer. 2021;:ePub

Ajdari A, Xie Y, Richter C, Niyazi M, Duda DG, Hong TS, Bortfeld T

Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers.
JCO Clin Cancer Inform. 2021;5:315-325 - PMID: 33764817 - PMCID: PMC8462658 - DOI: 10.1200/CCI.20.00118

Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature. 2021;592(7854):450-456 - PMID: 33762733 - PMCID: PMC8046670 - DOI: 10.1038/s41586-021-03362-0

Li W, Li S, Chen IX, Liu Y, Ramjiawan RR, Leung CH, Gerweck LE, Fukumura D, Loeffler JS, Jain RK, Duda DG, Huang P

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Radiat Oncol. 2021;16(1):48 - PMID: 33663521 - PMCID: PMC7934382 - DOI: 10.1186/s13014-021-01775-9

Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG

Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Gut. 2021;71(1):185-193 - PMID: 33431577 - PMCID: PMC8666816 - DOI: 10.1136/gutjnl-2020-322493

Nayak L, Molinaro AM, Peters KB, Clarke JL, Jordan JT, de Groot JF, Nghiemphu PL, Kaley TJ, Colman H, McCluskey C, Gaffey S, Smith T, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA

Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients.
Clin Cancer Res. 2021;27(4):1048-1057 - PMID: 33199490 - PMCID: PMC8284901 - DOI: 10.1158/1078-0432.CCR-20-2500

Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT

Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients.
Neurooncol Adv. 2020;2(1):vdaa157 - PMID: 33392506 - PMCID: PMC7764510 - DOI: 10.1093/noajnl/vdaa157

Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG

Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Clin Cancer Res. 2020;26(23):6158-6167 - PMID: 32878766 - DOI: 10.1158/1078-0432.CCR-20-1310

Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020;8(2):ePub - PMID: 33234602 - PMCID: PMC7689089 - DOI: 10.1136/jitc-2020-001435

Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO

Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.
Oncology. 2020;98(12):836-846 - PMID: 33027788 - PMCID: PMC7704605 - DOI: 10.1159/000502482

Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, Duda DG, Roberts LR, Russell SJ, Peng KW, Borad MJ

Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers.
Mol Ther Oncolytics. 2020;18:546-555 - PMID: 32839735 - PMCID: PMC7437509 - DOI: 10.1016/j.omto.2020.08.007

Martin JD, Duda DG, Jain RK

Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?
Circ Res. 2020;127(6):724-726 - PMID: 32853096 - PMCID: PMC7462096 - DOI: 10.1161/CIRCRESAHA.120.317720

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG

Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Hepatology. 2020;71(4):1247-1261 - PMID: 31378984 - PMCID: PMC7000304 - DOI: 10.1002/hep.30889

Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I

Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients.
Cancers (Basel). 2020;12(5):ePub - PMID: 32443546 - PMCID: PMC7281651 - DOI: 10.3390/cancers12051275

Kongpetch S, Jusakul A, Lim JQ, Ng CCY, Chan JY, Rajasegaran V, Lim TH, Lim KH, Choo SP, Dima S, Popescu I, Duda DG, Kukongviriyapan V, Khuntikeo N, Pairojkul C, Rozen SG, Tan P, Teh BT

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
JCO Glob Oncol. 2020;6:628-638 - PMID: 32315234 - PMCID: PMC7193781 - DOI: 10.1200/GO.20.00030

Chen J, Duda DG

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - PMCID: PMC6997488 - DOI: 10.1016/j.ebiom.2020.102644

Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M

Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8

Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T

Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res. 2020;26(1):206-212 - PMID: 31558474 - PMCID: PMC7139851 - DOI: 10.1158/1078-0432.CCR-19-1739

Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565

Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
J Clin Oncol. 2019;37(35):3446-3454 - PMID: 31626572 - PMCID: PMC7098833 - DOI: 10.1200/JCO.19.01367

Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Cancer Med. 2019;8(13):5988-5994 - PMID: 31444999 - PMCID: PMC6792497 - DOI: 10.1002/cam4.2505

Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, Duda DG, Guimaraes AR, Hong TS, Bortfeld TR, Seco J

Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy.
Clin Transl Radiat Oncol. 2019;18:113-119 - PMID: 31341986 - PMCID: PMC6630151 - DOI: 10.1016/j.ctro.2019.04.013

Saftoiu A, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, Duda DG, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P

Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol.
Endosc Ultrasound. 2019;8(4):235-240 - PMID: 31249159 - PMCID: PMC6714481 - DOI: 10.4103/eus.eus_16_19

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep. 2019;9(1):8721 - PMID: 31197238 - PMCID: PMC6565804 - DOI: 10.1038/s41598-019-44365-2

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019;5(7):1020-1027 - PMID: 31145418 - PMCID: PMC6547247 - DOI: 10.1001/jamaoncol.2019.0892

Amoozgar Z, Jain RK, Duda DG

Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer. 2019;125(13):2213-2221 - PMID: 30913304 - PMCID: PMC6763367 - DOI: 10.1002/cncr.32029

Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
NPJ Breast Cancer. 2019;5:4 - PMID: 30675514 - PMCID: PMC6333771 - DOI: 10.1038/s41523-018-0100-8

Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol. 2018;2:22 - PMID: 30374460 - PMCID: PMC6194077 - DOI: 10.1038/s41698-018-0065-y

Lee EQ, Duda DG, Muzikansky A, Gerstner E, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey SC, Batchelor T, Jain RK, Wen PY

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
Clin Cancer Res. 2018;24(19):4643-4649 - PMID: 29941486 - DOI: 10.1158/1078-0432.CCR-18-1025

Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG

Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
Int J Radiat Oncol Biol Phys. 2018;101(5):1222-1225 - PMID: 29859792 - PMCID: PMC6050125 - DOI: 10.1016/j.ijrobp.2018.04.026

Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Sci Transl Med. 2018;10(432):ePub - PMID: 29540614 - PMCID: PMC5936748 - DOI: 10.1126/scitranslmed.aag0945

Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol. 2018;15(5):325-340 - PMID: 29508855 - PMCID: PMC5921900 - DOI: 10.1038/nrclinonc.2018.29

Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y

Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics. 2018;8(4):894-905 - PMID: 29463989 - PMCID: PMC5817100 - DOI: 10.7150/thno.21168

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
NPJ Precis Oncol. 2017;1:ePub - PMID: 29202103 - PMCID: PMC5708878 - DOI: 10.1038/s41698-017-0020-3

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Oncolytic Virother. 2017;6:39-49 - PMID: 29184854 - PMCID: PMC5687448 - DOI: 10.2147/OV.S145262

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J. 2017;5(7):987-996 - PMID: 29163965 - PMCID: PMC5676550 - DOI: 10.1177/2050640617695698

Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK

A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101

Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov L, Gordan R, Rozen SG, Shibata T, Pairojkul C, Teh BT, Tan P

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Cancer Discov. 2017;7(10):1116-1135 - PMID: 28667006 - PMCID: PMC5628134 - DOI: 10.1158/2159-8290.CD-17-0368

Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Sci Transl Med. 2017;9(391):ePub - PMID: 28539475 - PMCID: PMC5917603 - DOI: 10.1126/scitranslmed.aal4682

David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z. Alexander Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Yongchul Song, Carlotta Costa, Kamila Naxerova, Christina S. F. Wong, Jonas Kloepper,
Rita Das, Angela Tam, Jantima Tanboon, Dan G. Duda, C. Ryan Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Monica V. Estrada, Robert Schlegel, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Science Translational Medicine. 2017;9(391):eaal4682

Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
Onco Targets Ther. 2017;10:1403-1412 - PMID: 28424556 - PMCID: PMC5344425 - DOI: 10.2147/OTT.S111681

Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK

Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.
Am J Cancer Res. 2017;7(3):484-502 - PMID: 28401006 - PMCID: PMC5385638

Ramjiawan RR, Griffioen AW, Duda DG

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis. 2017;20(2):185-204 - PMID: 28361267 - PMCID: PMC5439974 - DOI: 10.1007/s10456-017-9552-y

Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Sci Rep. 2017;7:44123 - PMID: 28276530 - PMCID: PMC5343435 - DOI: 10.1038/srep44123

Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Cancer. 2017;123(11):1979-1988 - PMID: 28192597 - PMCID: PMC5444988 - DOI: 10.1002/cncr.30571

Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.
Ecancermedicalscience. 2016;10:689 - PMID: 27994645 - PMCID: PMC5130328 - DOI: 10.3332/ecancer.2016.689

Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK

Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27908927 - PMCID: PMC5131752 - DOI: 10.1101/cshperspect.a031195

Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK, Fukumura D

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Sci Transl Med. 2016;8(360):360ra135 - PMID: 27733559 - PMCID: PMC5457741 - DOI: 10.1126/scitranslmed.aaf5219

Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK

Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.
Cold Spring Harb Perspect Med. 2016;6(12):ePub - PMID: 27663981 - PMCID: PMC5131751 - DOI: 10.1101/cshperspect.a027094

Popp I, Grosu AL, Niedermann G, Duda DG

Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.
Radiother Oncol. 2016;120(2):185-94 - PMID: 27495145 - DOI: 10.1016/j.radonc.2016.07.013

Chng KR, Chan SH, Ng AH, Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DM, Lim KH, Soetinko R, Ong CK, Duda DG, Dima S, Popescu I, Wongkham C, Feng Z, Yeoh KG, Teh BT, Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Ngeow J, Nagarajan N

Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.
EBioMedicine. 2016;8:195-202 - PMID: 27428430 - PMCID: PMC4919562 - DOI: 10.1016/j.ebiom.2016.04.034

Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113

Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY

A protein and mRNA expression-based classification of gastric cancer.
Mod Pathol. 2016;29(7):772-84 - PMID: 27032689 - DOI: 10.1038/modpathol.2016.55

Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
J Clin Oncol. 2016;34(14):1669-75 - PMID: 26976425 - PMCID: PMC4872317 - DOI: 10.1200/JCO.2015.64.3817

Hato T, Zhu AX, Duda DG

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313 - PMID: 26865127 - PMCID: PMC5619018 - DOI: 10.2217/imt.15.126

Hayano K, Kulkarni NM, Duda DG, Heist RS, Sahani DV

Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy.
AJR Am J Roentgenol. 2016;206(5):987-93 - PMID: 26934729 - DOI: 10.2214/AJR.15.15528

Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam T, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel JA, Krop I, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D

PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity.
Clin Cancer Res. 2016;22(12):2993-3004 - PMID: 26861455 - PMCID: PMC4911258 - DOI: 10.1158/1078-0432.CCR-15-1839

Botezatu A, Bleotu C, Nastase A, Anton G, Bacalbasa N, Duda D, Dima SO, Popescu I

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
Cancer Genomics Proteomics. 2015;12(1):21-30 - PMID: 25560641

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Clin Cancer Res. 2015;21(16):3610-8 - PMID: 25910950 - PMCID: PMC4790106 - DOI: 10.1158/1078-0432.CCR-14-3220

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Hepatology. 2015;61(5):1591-602 - PMID: 25529917 - PMCID: PMC4406806 - DOI: 10.1002/hep.27665

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Proc Natl Acad Sci U S A. 2015;112(46):14325-14330 - PMID: 26578779 - PMCID: PMC4655544 - DOI: 10.1073/pnas.1518808112

Chen Y, Duda DG

Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
Oncoimmunology. 2015;4(10):e1029703 - PMID: 26451297 - PMCID: PMC4589048 - DOI: 10.1080/2162402X.2015.1029703

Samuel R, Duda DG, Fukumura D, Jain RK

Vascular diseases await translation of blood vessels engineered from stem cells.
Sci Transl Med. 2015;7(309):309rv6 - PMID: 26468328 - PMCID: PMC4799660 - DOI: 10.1126/scitranslmed.aaa1805

Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY

Familial Gastric Cancers.
Oncologist. 2015;20(12):1365-1377 - PMID: 26424758 - PMCID: PMC4679084 - DOI: 10.1634/theoncologist.2015-0205

Jain RK, Fukumura D, Duda DG

From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey.
Cancer J. 2015;21(4):235-236 - PMID: 26222072 - PMCID: PMC4791947 - DOI: 10.1097/PPO.0000000000000136

Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG

An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Nat Protoc. 2015;10(8):1264-1274 - PMID: 26203823 - PMCID: PMC4800979 - DOI: 10.1038/nprot.2015.080

Goyal L, Chong DQ, Duda DG, Zhu AX

Chemotherapy and antiangiogenics in biliary tract cancer.
Lancet Oncol. 2015;16(8):882-3 - PMID: 26179202 - DOI: 10.1016/S1470-2045(15)00093-5

Lemon CM, Karnas E, Han X, Bruns OT, Kempa TJ, Fukumura D, Bawendi MG, Jain RK, Duda DG, Nocera DG

Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors.
J Am Chem Soc. 2015;137(31):9832-42 - PMID: 26149349 - PMCID: PMC4750386 - DOI: 10.1021/jacs.5b04765

Duda DG, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK

Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.
Proc Natl Acad Sci U S A. 2015;112(27):E3454 - PMID: 26080434 - PMCID: PMC4500270 - DOI: 10.1073/pnas.1507225112

Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
J Natl Cancer Inst. 2015;107(9):ePub - PMID: 26063793 - PMCID: PMC4651102 - DOI: 10.1093/jnci/djv155

Jain RK, Fukumura D, Duda DG

Lessons From 30 Years of Teaching About the Microenvironment of Tumors.
Cancer J. 2015;21(3):137 - PMID: 26049690 - PMCID: PMC4792516 - DOI: 10.1097/PPO.0000000000000119

Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Neuro Oncol. 2015;17(10):1386-92 - PMID: 26008604 - PMCID: PMC4578584 - DOI: 10.1093/neuonc/nov085

Hayano K, Tian F, Kambadakone AR, Yoon SS, Duda DG, Ganeshan B, Sahani DV

Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma.
J Comput Assist Tomogr. 2015;39(4):607-612 - PMID: 25793653 - PMCID: PMC4504795 - DOI: 10.1097/RCT.0000000000000239

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK

Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma.
J Clin Oncol. 2015;33(10):1197-213 - PMID: 25713439 - PMCID: PMC4517055 - DOI: 10.1200/JCO.2014.55.9575

Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG

Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304 - DOI: 10.1073/pnas.1421632111

Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Proc Natl Acad Sci U S A. 2015;112(5):1547-52 - PMID: 25605928 - PMCID: PMC4321320 - DOI: 10.1073/pnas.1424024112

Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV

CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression.
AJR Am J Roentgenol. 2015;204(1):W11-8 - PMID: 25539263 - PMCID: PMC4479405 - DOI: 10.2214/AJR.13.12412

Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG

Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Hepatology. 2014;59(4):1435-47 - PMID: 24242874 - PMCID: PMC3966948 - DOI: 10.1002/hep.26790

Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P

Translation of anticancer efficacy from nonclinical models to the clinic.
CPT Pharmacometrics Syst Pharmacol. 2014;3:e128 - PMID: 25098530 - PMCID: PMC4150926 - DOI: 10.1038/psp.2014.28

Richter C, Seco J, Hong TS, Duda DG, Bortfeld T

Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism.
Med Hypotheses. 2014;83(4):477-81 - PMID: 25175713 - DOI: 10.1016/j.mehy.2014.08.004

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK

Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation.
Neuro Oncol. 2014;16 Suppl 3:iii12 - PMID: 25165209 - PMCID: PMC4144509

Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK

Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.
J Natl Cancer Inst. 2014;106(8):ePub - PMID: 25082335 - DOI: 10.1093/jnci/dju187

Jain RK, Fukumura D, Duda DG

Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy.
In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (Editor: LM McManus & RN Mitchell). Elsevier Press, Oxford. 2014;:(in press)

Jain RK, Duda DG

Molecular Pathophysiology of Tumors.
In: Principles and Practice of Radiation Oncology, 6th Edition (Editors: E. C. Halperin, C. A. Parez, L. W. Brady), Lippincott, Williams & Wilkins, New York. 2014;Chapter 4:(in press)

Hato T, Goyal L, Greten TF, Duda DG, Zhu AX

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.
Hepatology. 2014;60(5):1776-82 - PMID: 24912948 - PMCID: PMC4211962 - DOI: 10.1002/hep.27246

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG

A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180 - DOI: 10.1016/j.ijrobp.2014.03.034

Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima SO, Popescu I

Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells.
Pancreas. 2014;43(5):795-800 - PMID: 24658318 - DOI: 10.1097/MPA.0000000000000106

Bucur O, Almasan A, Nikolajczyk BS, Nicolson GL, Lawler J, Velculescu VE, Draghici S, Leabu M, Avram D, Bucur I, Calautti E, Calin GA, Chauhan SC, Ciubotaru M, Constantinescu SN, Datta D, Duda DG, Friedman MT, Galardy PJ, Harris BT, Huarte M, Khalil AM, Marchetti D, Movileanu L, Nat R, Nucera C, Popa-Wagner A, Stancu AL, Zhu S, Liehn EA

Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry.
Discoveries (Craiova). 2013;1(1):e1 - PMID: 32309535 - PMCID: PMC6919543 - DOI: 10.15190/d.2013.1

Duda DG

Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.
ISRN Cell Biol. 2013;2012:ePub - PMID: 24340224 - PMCID: PMC3856765 - DOI: 10.5402/2012/587259

Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 2013;45(12):1474-8 - PMID: 24185513 - DOI: 10.1038/ng.2806

Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK

Benefits of Vascular Normalization Are Dose and Time Dependent--Letter.
Cancer Res. 2013;73(23):7144-6 - PMID: 24265277 - PMCID: PMC3876035 - DOI: 10.1158/0008-5472.CAN-13-1989

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Proc Natl Acad Sci U S A. 2013;110(47):19059-64 - PMID: 24190997 - PMCID: PMC3839699 - DOI: 10.1073/pnas.1318022110

Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent F, Duda DG, Stuart K

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2 in Patients with Advanced Hepatocellular Cancer.
Clin Cancer Res. 2013;19(23):6614-23 - PMID: 24088738 - PMCID: PMC4795808 - DOI: 10.1158/1078-0432.CCR-13-1442

Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, Padera TP, Duda DG, Fukumura D, Jain RK

Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
J Natl Cancer Inst. 2013;105(16):1188-1201 - PMID: 23899555 - PMCID: PMC3748004 - DOI: 10.1093/jnci/djt164

Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A, Buecker C, Schäfer R, Han X, Au P, Scadden DT, Duda DG, Fukumura D, Jain RK

Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
Proc Natl Acad Sci U S A. 2013;110(31):12774-9 - PMID: 23861493 - PMCID: PMC3732948 - DOI: 10.1073/pnas.1310675110

Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Neuro Oncol. 2013;15(8):1079-87 - PMID: 23828240 - PMCID: PMC3714160 - DOI: 10.1093/neuonc/not082

Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
J Hematol Oncol. 2013;6(1):51 - PMID: 23842041 - PMCID: PMC3722053 - DOI: 10.1186/1756-8722-6-51

Duda DG, Munn LL, Jain RK

Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?
J Natl Cancer Inst. 2013;105(11):762-5 - PMID: 23670727 - PMCID: PMC3672078 - DOI: 10.1093/jnci/djt114

Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK

Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
Cell. 2013;152(5):1065-76 - PMID: 23452854 - PMCID: PMC3587980 - DOI: 10.1016/j.cell.2013.01.036

Huang Y, Goel S, Duda DG, Fukumura D, Jain RK

Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Cancer Res. 2013;73(10):2943-8 - PMID: 23440426 - PMCID: PMC3655127 - DOI: 10.1158/0008-5472.CAN-12-4354

Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, Jackson McCleary N, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG

Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423 - DOI: 10.1158/1078-0432.CCR-12-3041

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Proc Natl Acad Sci U S A. 2012;109(43):17561-6 - PMID: 23045683 - PMCID: PMC3491458 - DOI: 10.1073/pnas.1215397109

Duda DG, Willett CG

Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?
Oncology (Williston Park). 2012;26(8):741-3 - PMID: 22957407 - PMCID: PMC3682651

Kozin SV, Duda DG, Munn LL, Jain RK

Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?
J Natl Cancer Inst. 2012;104(12):899-905 - PMID: 22572994 - PMCID: PMC3379722 - DOI: 10.1093/jnci/djs239

Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PLoS One. 2012;7(6):e38231 - PMID: 22701615 - PMCID: PMC3373492 - DOI: 10.1371/journal.pone.0038231

Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I

An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma.
Pancreas. 2012;41(7):1001-7 - PMID: 22722257 - DOI: 10.1097/MPA.0b013e3182546e13

Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG

Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170 - DOI: 10.1634/theoncologist.2011-0321

Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PLoS One. 2012;7(2):e26331 - PMID: 22347360 - PMCID: PMC3274514 - DOI: 10.1371/journal.pone.0026331

Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK

An isolated tumor perfusion model in mice.
Nat Protoc. 2012;7(4):749-55 - PMID: 22441293 - PMCID: PMC3375334 - DOI: 10.1038/nprot.2012.030

Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG

Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.
Nat Protoc. 2012;7(4):756-62 - PMID: 22441294 - PMCID: PMC3380105 - DOI: 10.1038/nprot.2012.031

Duyverman AM, Kohno M, Duda DG, Jain RK, Fukumura D

A transient parabiosis skin transplantation model in mice.
Nat Protoc. 2012;7(4):763-70 - PMID: 22441295 - PMCID: PMC3375333 - DOI: 10.1038/nprot.2012.032

Dawson MR, Chae SS, Jain RK, Duda DG

Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression.
Am J Cancer Res. 2011;1(2):144-54 - PMID: 21822499 - PMCID: PMC3150110

Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK

Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010

Kozin SV, Duda DG, Munn LL, Jain RK

Is vasculogenesis crucial for the regrowth of irradiated tumours?
Nat Rev Cancer. 2011;11(7):532 - PMID: 21701514 - PMCID: PMC4790119 - DOI: 10.1038/nrc2007-c1

Zhu AX, Duda DG, Sahani DV, Jain RK

HCC and angiogenesis: possible targets and future directions.
Nat Rev Clin Oncol. 2011;8(5):292-301 - PMID: 21386818 - PMCID: PMC3266719 - DOI: 10.1038/nrclinonc.2011.30

Duda DG

Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer
Angiogenesis Foundation CME e-publication. 2011;:ePub

di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK

Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape.
Cancer Res. 2011;71(1):19-28 - PMID: 21199795 - PMCID: PMC3074948 - DOI: 10.1158/0008-5472.CAN-10-2602

Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7

Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK

Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Proc Natl Acad Sci U S A. 2011;108(9):3725-30 - PMID: 21321210 - PMCID: PMC3048115 - DOI: 10.1073/pnas.1100446108

Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636

Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33 - PMID: 21833345 - PMCID: PMC3151740 - DOI: 10.1016/j.cloc.2011.04.003

Fukumura D, Duda DG, Munn LL, Jain RK

Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
Microcirculation. 2010;17(3):206-25 - PMID: 20374484 - PMCID: PMC2859831 - DOI: 10.1111/j.1549-8719.2010.00029.x

Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK

Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109 - DOI: 10.1073/pnas.1016234107

Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK

A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(8):845-51 - PMID: 20667969 - PMCID: PMC3078712 - DOI: 10.1634/theoncologist.2010-0030

Duda DG, Jain RK

Premetastatic lung niche: is vascular endothelial growth factor receptor 1 activation required?
Cancer Res. 2010;70(14):5670-3 - PMID: 20587530 - PMCID: PMC2919170 - DOI: 10.1158/0008-5472.CAN-10-0119

Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Oncologist. 2010;15(6):577-83 - PMID: 20484123 - PMCID: PMC3061828 - DOI: 10.1634/theoncologist.2010-0029

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010;28(17):2817-23 - PMID: 20458050 - PMCID: PMC2903316 - DOI: 10.1200/JCO.2009.26.3988

Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG

Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.
Cancer Res. 2010;70(14):5679-85 - PMID: 20631066 - PMCID: PMC2918387 - DOI: 10.1158/0008-5472.CAN-09-4446

Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT

The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients.
Nat Clin Pract Oncol. 2009;6:229-36

Perentes JY, Duda DG, Jain RK

Visualizing anti-tumor immune responses in vivo.
Dis Model Mech. 2009;2(3-4):107-10 - PMID: 19259379 - PMCID: PMC2650205 - DOI: 10.1242/dmm.001842

Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
J Clin Oncol. 2009;27(18):3020-6 - PMID: 19470921 - PMCID: PMC2702234 - DOI: 10.1200/JCO.2008.21.1771

Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG

Biomarkers of response and resistance to antiangiogenic therapy.
Nat Rev Clin Oncol. 2009;6(6):327-38 - PMID: 19483739 - PMCID: PMC3057433 - DOI: 10.1038/nrclinonc.2009.63

Zhu AX, Duda DG, Sahani DV, Jain RK

Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Cancer J. 2009;15(4):263-8 - PMID: 19672141 - PMCID: PMC4792519 - DOI: 10.1097/PPO.0b013e3181af5e35

Au P, Tam J, Duda DG, Lin PC, Munn LL, Fukumura D, Jain RK

Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo.
Am J Pathol. 2009;175(1):294-302 - PMID: 19477947 - PMCID: PMC2708815 - DOI: 10.2353/ajpath.2009.080887

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
J Clin Oncol. 2009;27(18):3027-35 - PMID: 19470923 - PMCID: PMC2702235 - DOI: 10.1200/JCO.2008.20.9908

Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Nat Rev Clin Oncol. 2009;6(4):229-36 - PMID: 19333229 - PMCID: PMC4793889 - DOI: 10.1038/nrclinonc.2009.14

Dawson MR, Duda DG, Fukumura D, Jain RK

VEGFR1-activity-independent metastasis formation.
Nature. 2009;461(7262):E4; discussion E5 - PMID: 19759568 - PMCID: PMC3065241 - DOI: 10.1038/nature08254

Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK

VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.
PLoS One. 2009;4(9):e6525 - PMID: 19763275 - PMCID: PMC2744279 - DOI: 10.1371/journal.pone.0006525

Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099

Jain RK, Duda DG, Sorensen AG

Emerging paradigms and potential biomarkers of response and resistance in anatiangiogenic therapy of cancer
ASCO 2009 Educational Book. 2009;:716-21

Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y

Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials.
Int J Radiat Oncol Biol Phys. 2009;74(5):1580-91 - PMID: 19540073 - DOI: 10.1016/j.ijrobp.2009.03.047

Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK

Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.
PLoS One. 2009;4(3):e4974 - PMID: 19333381 - PMCID: PMC2659427 - DOI: 10.1371/journal.pone.0004974

Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
J Clin Oncol. 2009;27(15):2542-52 - PMID: 19332720 - PMCID: PMC2739611 - DOI: 10.1200/JCO.2008.19.9356

Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009;69(13):5296-300 - PMID: 19549889 - PMCID: PMC2824172 - DOI: 10.1158/0008-5472.CAN-09-0814

Jones R, Capen DE, Jacobson M, Cohen KS, Scadden DT, Duda DG

VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).
J Cell Mol Med. 2009;13(9B):3720-9 - PMID: 19426150 - PMCID: PMC2832073 - DOI: 10.1111/j.1582-4934.2009.00785.x

Willett CG, Duda DG, Xu L, diTomaso E, Boucher Y, Czito B, Ancukiewicz M, Clark J, Carroll M, Lauwers G, Jain RK

Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464

Jain RK, Duda DG, Batchelor TT, Sorensen AG, Willett CG

Normalization of tumor vasculature and microenvironment.
In: Angiogenesis: An Integrative Approach from Science to Medicine (Editors: W. D. Figg and J. Folkman), Springer. 2008;:173-282

Jain RK, Duda DG

Vascular and interstitial biology of tumors
In: Clinical Oncology. 4th Edition, (Editors: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG), Elsevier, Philadelphia. 2008;:105-24

Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG

A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):388-97 - PMID: 18323810 - PMCID: PMC2676340 - DOI: 10.1038/nprot.2007.537

Jones RC, Capen D, Petersen B, Jain RK, Duda DG

A protocol for a lung neovascularization model in rodents.
Nat Protoc. 2008;3(3):378-87 - PMID: 18323809 - PMCID: PMC2676330 - DOI: 10.1038/nprot.2007.536

Huang P, Duda DG, Jain RK, Fukumura D

Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.
Comp Med. 2008;58(3):253-63 - PMID: 18589867 - PMCID: PMC2693079

Jain RK, Batchelor TT, Duda DG, Willett CG

Normalization of tumor vasculature and microenvironment.
In: Antiangiogenic Agents in Cancer Therapy. (Editors: Beverly Teicher and Lee Ellis), Humana Press. 2007;:261-76

Jain RK, Duda DG

Normalization of tumor vasculature and microenvironment by antiangiogenic therapy.
In: Angiogenesis: Mechanisms and Cancer Therapy (Editors: Dieter Marm and Norbert E. Fusenig), Springer-Verlag, Berlin. 2007;:577-92

Jain RK, Duda DG

Angiogenesis in Solid Tumors
In: Antiangiogenic Cancer Therapy (Editors: James L. Abbruzzese, Darren W. Davis and Roy S. Herbst), CRC Press, Boca Raton. 2007;:43-90

Willett CG, Duda DG, Jain RK

Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer.
Current Colorectal Cancer Reports. 2007;3:94-98

Duda DG, Cohen KS, Au P, Scadden DT, Willett CG, Jain RK

Detection of circulating endothelial cells: CD146- based magnetic separation enrichment or flow cytometric assay?
J Clin Oncol. 2007;25:e3-e5

Duda DG

Endothelial cell-based therapy for hematopoiesis
Blood. 2007;109(6):2272-3

Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007;11(1):83-95 - PMID: 17222792 - PMCID: PMC2748664 - DOI: 10.1016/j.ccr.2006.11.021

Duda DG, Cohen KS, Scadden DT, Jain RK

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.
Nat Protoc. 2007;2(4):805-10 - PMID: 17446880 - PMCID: PMC2686125 - DOI: 10.1038/nprot.2007.111

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT

Angiogenesis in brain tumours.
Nat Rev Neurosci. 2007;8(8):610-22 - PMID: 17643088 - DOI: 10.1038/nrn2175

Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT

Antiangiogenic agents for the treatment of glioblastoma.
Expert Opin Investig Drugs. 2007;16(12):1895-908 - PMID: 18041999 - DOI: 10.1517/13543784.16.12.1895

Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK

Targeted therapy in rectal cancer.
Oncology (Williston Park). 2007;21(9):1055-65; discussion 1065, 1070, 1075 passim - PMID: 17910311 - PMCID: PMC2686129

Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol. 2007;4(5):316-21 - PMID: 17464339 - PMCID: PMC2686127 - DOI: 10.1038/ncponc0813

Duda DG

American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.
IDrugs. 2007;10(6):366-9 - PMID: 17641996

Duda DG, Batchelor TT, Willett CG, Jain RK

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
Trends Mol Med. 2007;13(6):223-30 - PMID: 17462954 - PMCID: PMC2686126 - DOI: 10.1016/j.molmed.2007.04.001

Duda DG, Jain RK, Willett CG

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120 - DOI: 10.1200/JCO.2007.11.3985

Jain RK, Duda DG, Clark JW, Loeffler JS

Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
Nat Clin Pract Oncol. 2006;3(1):24-40 - PMID: 16407877 - DOI: 10.1038/ncponc0403

Duda DG

Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
Cancer Res. 2006;66(8):3967-70 - PMID: 16618712 - DOI: 10.1158/0008-5472.CAN-05-4536

Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH

Platelet-derived growth factor receptor-beta in Gorham's disease.
Nat Clin Pract Oncol. 2006;3(12):693-7 - PMID: 17139320 - PMCID: PMC2693369 - DOI: 10.1038/ncponc0660

Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD

Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.
Proc Natl Acad Sci U S A. 2006;103(4):855-60 - PMID: 16418262 - PMCID: PMC1348013 - DOI: 10.1073/pnas.0510412103

Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK

Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.
J Clin Oncol. 2006;24(9):1449-53 - PMID: 16549839 - PMCID: PMC2718681 - DOI: 10.1200/JCO.2005.04.2861

Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK

Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Semin Oncol. 2006;33(5 Suppl 10):S35-40 - PMID: 17145523 - PMCID: PMC2686124 - DOI: 10.1053/j.seminoncol.2006.08.007

Jain RK, Au P, Tam J, Duda DG, Fukumura D

Engineering vascularized tissue.
Nat Biotechnol. 2005;23(7):821-3 - PMID: 16003365 - DOI: 10.1038/nbt0705-821

Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
J Clin Oncol. 2005;23(31):8136-9 - PMID: 16258121 - DOI: 10.1200/JCO.2005.02.5635

Duda DG, Jain RK

Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow.
J Clin Invest. 2005;115(3):596-8 - PMID: 15765145 - PMCID: PMC1052004 - DOI: 10.1172/JCI24511

Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK

Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.
Nat Med. 2005;11(6):678-82 - PMID: 15880117 - PMCID: PMC2686110 - DOI: 10.1038/nm1247

Willett CG, Duda DG, Fischman A, Jain RK

Correspondence: PET concerns in bevacizumab treatment
Nature Medicine. 2004;10:561

Duda DG, Fukumura D, Jain RK

Role of eNOS in neovascularization: NO for endothelial progenitor cells.
Trends Mol Med. 2004;10(4):143-5 - PMID: 15162796 - DOI: 10.1016/j.molmed.2004.02.001

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med. 2004;10(2):145-7 - PMID: 14745444 - PMCID: PMC2693485 - DOI: 10.1038/nm988

Duda DG, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, Seed B, Jain RK

Differential transplantability of tumor-associated stromal cells.
Cancer Res. 2004;64(17):5920-4 - PMID: 15342367 - DOI: 10.1158/0008-5472.CAN-04-1268

Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S

The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Pancreas. 2004;28(3):311-6 - PMID: 15084978 - DOI: 10.1097/00006676-200404000-00019

Jain RK, Duda DG

Role of bone marrow-derived cells in tumor angiogenesis and treatment.
Cancer Cell. 2003;3(6):515-6 - PMID: 12842078 - DOI: 10.1016/s1535-6108(03)00138-7

Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG

Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer.
Angiogenesis. 2003;6(1):15-24 - PMID: 14517400 - DOI: 10.1023/a:1025803600840

Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A

Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Oncogene. 2003;22(44):6857-64 - PMID: 14534532 - DOI: 10.1038/sj.onc.1206751

Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK

Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA

Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S

Gene therapy for pancreatic cancer based on genetic characterization of the disease.
J Hepatobiliary Pancreat Surg. 2002;9(1):32-8 - PMID: 12021895 - DOI: 10.1007/s005340200002

Lefter LP, Furukawa T, Sunamura M, Duda DG, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A

Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines.
Genes Chromosomes Cancer. 2002;34(2):234-42 - PMID: 11979557 - DOI: 10.1002/gcc.10060

Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S

Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.
Pancreas. 2002;25(2):111-21 - PMID: 12142732 - DOI: 10.1097/00006676-200208000-00001

Ding L, Sunamura M, Kodama T, Yamauchi J, Duda DG, Shimamura H, Shibuya K, Takeda K, Matsuno S

In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells
Br J Cancer. 2001;85:431-8 - PMID: 11487277 - PMCID: PMC2364062 - DOI: 10.1054/bjoc.2001.1911

Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S

The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice.
Pancreas. 2000;20(3):227-33 - PMID: 10766447 - DOI: 10.1097/00006676-200004000-00002

Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S

Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Cancer Res. 2000;60(4):1111-6 - PMID: 10706132

Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H

Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus.
Hum Gene Ther. 2000;11(2):223-35 - PMID: 10680837 - DOI: 10.1089/10430340050015978
248